Skip to main content

Voyager Therapeutics, Inc. (VYGR)

NASDAQ: VYGR · IEX Real-Time Price · USD
2.65
-0.28 (-9.56%)
At close: Dec 3, 2021 4:00 PM
2.68
0.03 (1.13%)
After-hours:Dec 3, 2021 7:55 PM EST

Company Description

Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases.

The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia.

The company has strategic collaboration agreements with the University of Massachusetts; and ClearPoint Neuro, Inc., as well as collaborations with Thermo Fisher Scientific and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs.

It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products.

Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Voyager Therapeutics, Inc.
Voyager Therapeutics Logo
CountryUnited States
Founded2013
IPO DateNov 11, 2015
IndustryBiotechnology
SectorHealth Care
Employees177
CEOG. Andre Turenne

Contact Details

Address:
75 Sidney St
Cambridge, Massachusetts 02139-4134
United States
Phone857 259 5340
Websitevoyagertherapeutics.com

Stock Details

Ticker SymbolVYGR
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0001640266

Key Executives

NamePosition
Michael J. Higgins M.B.A.Interim Chief Executive Officer, President and Chairman
Dr. Glenn F. Pierce M.D., Ph.D.Independent Director, Interim Chief Scientific Officer and Chief Medical Officer
Robert W. HessleinSenior Vice President and General Counsel
G. Andre TurenneAdvisor
Dr. Steven M. Paul M.D.Executive Science Advisor and Director
Dr. Krystof Bankiewicz M.D., Ph.D.Founder
Dr. Guangping GaoFounder
Dr. Mark A. Kay M.D., Ph.D.Founder
Dr. Phillip D. ZamoreFounder
Julie BurekPrincipal Financial and Accounting Officer

Latest SEC Filings

DateTypeTitle
Nov 30, 20214Statement of changes in beneficial ownership of securities
Nov 30, 20213Initial statement of beneficial ownership of securities
Nov 19, 20218-KCurrent report
Nov 2, 202110-QQuarterly report [Sections 13 or 15(d)]
Nov 2, 20218-KCurrent report
Oct 22, 2021SC 13GStatement of acquisition of beneficial ownership by individuals
Oct 6, 20218-KCurrent report
Aug 9, 202110-QQuarterly report [Sections 13 or 15(d)]
Aug 9, 20218-KCurrent report
Jul 12, 2021SC 13G/AStatement of acquisition of beneficial ownership by individuals
View All SEC Filings